Lynch syndrome (hereditary non-polyposis colorectal cancer): Current concepts and approaches to management

Current Gastroenterology Reports

Volumn 7, Issue 5, 2005, Pages 412-420

  Ricciardiello, Luigi ^a   Boland, C Richard ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MISMATCH REPAIR PROTEIN PMS2; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN MUTL; PROTEIN MUTS;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CAUSE OF DEATH; COLORECTAL CANCER; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DNA REPAIR; DRUG TARGETING; FAMILIAL CANCER; FAMILY STUDY; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC PROCEDURES; HUMAN; MEDICAL SPECIALIST; NONHUMAN; PRACTICE GUIDELINE; REVIEW;

EID: 28244474487     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0012-2     Document Type: Review

References (90)

1. Boland CR: Evolution of the nomenclature for hereditary colorectal cancer. Fam Cancer 2005, 4:211-217.
2. Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995, 87:1114-1125.
3. Lynch HT, Krush AJ: Cancer family "G" revisited: 1895-1970. Cancer 1971, 27:1505-1511.
4. Lynch HT, Shaw MW, Magnuson CW, et al.: Hereditary factors in cancer: study of two large Midwestern kindreds. Arch Intern Med 1966, 117:206-212.
5. Boland CR, Troncale FJ: Familial colonic cancer without antecedent polyposis. Ann Intern Med 1984, 100:700-701.
6. Lynch HT, Kimberling W, Albano WA, et al.: Hereditary non-polyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer 1985, 56:934-938.
7. Mecklin JP, Sipponen P, Jarvinen HJ: Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 1986, 29:849-853.
8. Ponti G, Losi L, Di Cregorio C, et al.: Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005, 103:1018-1025.
9. Vasen HF, Mecklin JP, Khan PM, Lynch HT: The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-425.
10. Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116:1453-1456.
11. Ionov Y, Peinado MA, Malkhosyan S, et al.: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363:558-561.
12. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
13. Aaltonen LA, Peltomaki P, Leach FS, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260:812-816.
14. Fishel R: The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 2001, 61:7369-7374.
15. Bronner CE, Baker SM, Morrison PT, et al.: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994, 368:258-261.
16. Edelmann W, Yang K, Umar A, et al.: Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997, 91:467-477.
17. Fishel R, Lescoe MK, Rao MR, et al.: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1994, 77:167.
18. Kolodner RD, Tytell JD, Schmeits JL, et al.: Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999, 59:5068-5074.
19. Leach FS, Nicolaides NC, Papadopoulos N, et al.: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993, 75(6):1215-1225.
20. Peltomaki P, Aaltonen LA, Sistonen P, et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993, 260:810-812.
21. Wu Y, Berends MJ, Post JG, Mensink RG, et al.: Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology 2001, 120:1580-1587.
22. Hendriks YM, Wagner A, Morreau H, et al.: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127:17-25.
23. Nakagawa H, Lockman JC, Frankel WL, et al.: Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 2004, 64(14):4721-4727.
24. Truninger K, Menigatti M, Luz J, et al.: Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005, 128:1160-1171.
25. Boland CR, Fishel R: Form, function, proteins and basketball. Gastroenterology 2005, 129:751-755.
26. Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991, 51:3075-3079.
27. Loeb LA: Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994, 54:5059-5063.
28. Markowitz S, Wang J, Myeroff L, et al.: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
29. Rampino N, Yamamoto H, Ionov Y, et al.: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
30. Souza RF, Appel R, Yin J, et al.: Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 1996, 14:255-257.
31. Duval A, Hamelin R: Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002, 62:2447-2454.
32. Lengauer C: Aneuploidy and genetic instability in cancer. Semin Cancer Biol 2005, 15:43-49.
33. Syngal S, Fox EA, Li C, et al.: Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 1999, 282:247-253.
34. Lindor NM, Rabe K, Petersen GM, et al.: Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005, 293:1979-1985.
35. Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
36. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al.: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997, 89:1758-1762.
37. Umar A, Boland CR, Terdiman JP, J et al.: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
38. Jass JR: HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004, 3:93-100.
39. Pinol V, Castells A, Andreu M, et al.: Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005, 293:1986-1994.
40. Syngal S, Fox EA, Eng C, et al.: Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000, 37:641-645.
41. Wahlberg SS, Schmeits J, Thomas G, et al.: Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002, 62:3485-3492.
42. Suraweera N, Duval A, Reperant M, et al.: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002, 123:1804-1811.
43. Hampel H, Frankel WL, Martin E, et al.: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005, 352:1851-1860.
44. Lindor NM, Burgart LJ, Leontovich O, et al.: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002, 20:1043-1048.
45. Bala S, Peltomaki P: CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 2001, 61:6042-6045.
46. Frazier ML, O'Donnell FT, Kong S, et al.: Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 2001, 61:1269-1271.
47. Kong S, Amos CI, Luthra R, et al.: Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000, 60:249-252.
48. Maillet P, Chappuis PO, Vaudan G, et al.: A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. Int J Cancer 2000, 88:928-931.
49. Jones JS, Chi X, Gu X, et al.: p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004, 10:5845-5849.
50. Wu Y, Berends MJ, Sijmons RH, et al.: A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001, 29:137-138.
51. Lipkin SM, Wang V, Jacoby R, et al.: MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet 2000, 24:27-35.
52. Lu SL, Kawabata M, Imamura T, et al.: HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet 1998, 19:17-18.
53. Bian Y, Caldes T, Wijnen J, et al.: TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol 2005, 23:3074-3078.
54. Young J, Barker MA, Simms LA, et al.: Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005, 3:254-263.
55. Jass JR, Whitehall VL, Young J, Leggett BA: Emerging concepts in colorectal neoplasia. Gastroenterology 2002, 123:862-876.
56. Bandipalliam P, Garber J, Kolodner RD, Syngal S: Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. Gastroenterology 2004, 126:936-937.
57. Lynch HT, Coronel SM, Okimoto R, et al.: A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 2004, 291:718-724.
58. Wijnen J, van der KH, Vasen H, et al.: MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 1998, 20:326-328.
59. Casey G, Lindor NM, Papadopoulos N, et al.: Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA 2005, 293:799-809.
60. Whiteside D, McLeod R, Graham G, et al.: A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res 2002, 62:359-362.
61. Ricciardone MD, Ozcelik T, Cevher B, et al.: Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 1999, 59:290-293.
62. Bougeard G, Charbonnier F, Moerman A, et al.: Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003, 72:213-216.
63. Trimbath JD, Petersen GM, Erdman SH, et al.: Cafe-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer 2001, 1:101-105.
64. Mangold E, Pagenstecher C, Leister M, et al.: A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet 2004, 41:567-572.
65. Lynch HT, Lynch PM, Pester J, Fusaro RM: The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med 1981, 141:607-611.
66. Entius MM, Keller JJ, Drillenburg P, et al.: Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 2000, 6:1784-1789.
67. Jager AC, Bisgaard ML, Myrhoj T, et al.: Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Am J Hum Genet 1997, 61:129-138.
68. Lipkin SM, Rozek LS, Rennert G, et al.: The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet 2004, 36:694-699.
69. Gallinger S, Aronson M, Shayan K, et al.: Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 2004, 126:576-585.
70. Scheenstra R, Rijcken FE, Koornstra JJ, et al.: Rapidly progressive adenomatous polyposis in a patient with germline mutations in both the APC and MLH1 genes: the worst of two worlds. Gut 2003, 52:898-899.
71. Herman JG, Umar A, Polyak K, et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998, 95:6870-6875.
72. Cunningham JM, Christensen ER, Tester DJ, et al.: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998, 58:3455-3460.
73. Gryfe R, Kim H, Hsieh ET, et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77.
74. Miyakura Y, Sugano K, Konishi F, et al.: Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001, 121:1300-1309.
75. Samowitz WS, Curtin K, Ma KN, et al.: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001, 10:917-923.
76. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP: Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996, 110:682-687.
77. Ward R, Meagher A, Tomlinson I, et al.: Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001, 48:821-829.
78. Nagasaka T, Sasamoto H, Notohara K, et al.: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004, 22:4584-4594.
79. Chang DK, Ricciardiello L, Goel A, et al.: Steady-state regulation of the human DNA mismatch repair system. J Biol Chem 2000, 275:18424-18431.
80. Giardiello FM, Brensinger JD, Petersen GM: AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001, 121:198-213.
81. Vasen HF, Nagengast FM, Khan PM: Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995, 345:1183-1184.
82. Carethers JM, Chauhan DP, Fink D, et al.: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999, 117:123-131.
83. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003, 106:66-73.
84. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
85. Carethers JM, Smith EJ, Behling CA, et al.: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004, 126:394-401.
86. Ricciardiello L, Ceccarelli C, Angiolini G, et al.: High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res 2005, 11:4234-4240.
87. Leichman CG, Lenz HJ, Leichman L, et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997, 15:3223-3229.
88. Lenz HJ, Leichman CG, Danenberg KD, et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996, 14:176-182.
89. Tajima A, Hess MT, Cabrera BL, et al.: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004, 127:1678-1684.
90. Fallik D, Borrini F, Boige V, et al.: Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003, 63:5738-5744.